BACKGROUND AND PURPOSE: The purpose of this study was to design a radiation therapy treatment planning approach that would spare hematopoietically active bone marrow using [(18)F]FLT PET imaging. MATERIALS AND METHODS: We have developed an IMRT planning methodology to incorporate functional PET imaging using [(18)F]FLT scans. Plans were generated for two simulated cervical cancer patients, where pelvic active bone marrow regions were incorporated as avoidance regions based on the ranges: SUV4 ≥ 4; 4>SUV3 ≥ 3; and 3 > SUV2 ≥ 2. Dose objectives were set to reduce bone marrow volume that received 10 (V(10)) and 20 (V(20))Gy. RESULTS: Active bone marrow regions identified by [(18)F]FLT with an SUV ≥ 2, SUV ≥ 3, and SUV ≥ 4 represented an average of 43.0%, 15.3%, and 5.8%, respectively of the total osseous pelvis for the two cases studied. Improved dose-volume histograms for all identified bone marrow SUV volumes and decreases in V(10), and V(20) were achieved without clinically significant changes to PTV or OAR doses. CONCLUSIONS: Incorporation of [(18)F]FLT PET in IMRT planning provides a methodology to reduce radiation dose to active bone marrow without compromising PTV or OAR dose objectives in pelvic malignancies.
BACKGROUND AND PURPOSE: The purpose of this study was to design a radiation therapy treatment planning approach that would spare hematopoietically active bone marrow using [(18)F]FLT PET imaging. MATERIALS AND METHODS: We have developed an IMRT planning methodology to incorporate functional PET imaging using [(18)F]FLT scans. Plans were generated for two simulated cervical cancerpatients, where pelvic active bone marrow regions were incorporated as avoidance regions based on the ranges: SUV4 ≥ 4; 4>SUV3 ≥ 3; and 3 > SUV2 ≥ 2. Dose objectives were set to reduce bone marrow volume that received 10 (V(10)) and 20 (V(20))Gy. RESULTS: Active bone marrow regions identified by [(18)F]FLT with an SUV ≥ 2, SUV ≥ 3, and SUV ≥ 4 represented an average of 43.0%, 15.3%, and 5.8%, respectively of the total osseous pelvis for the two cases studied. Improved dose-volume histograms for all identified bone marrow SUV volumes and decreases in V(10), and V(20) were achieved without clinically significant changes to PTV or OAR doses. CONCLUSIONS: Incorporation of [(18)F]FLT PET in IMRT planning provides a methodology to reduce radiation dose to active bone marrow without compromising PTV or OAR dose objectives in pelvic malignancies.
Authors: Louis Bazire; Haoping Xu; Jean-Philippe Foy; Malika Amessis; Caroline Malhaire; Kim Cao; Anne De La Rochefordiere; Youlia M Kirova Journal: Br J Radiol Date: 2017-03-14 Impact factor: 3.039
Authors: Eric Dinges; Nicole Felderman; Sarah McGuire; Brandie Gross; Sudershan Bhatia; Sarah Mott; John Buatti; Dongxu Wang Journal: Radiother Oncol Date: 2015-05-13 Impact factor: 6.280
Authors: Xiaofan Xiong; Brian J Smith; Stephen A Graves; John J Sunderland; Michael M Graham; Brandie A Gross; John M Buatti; Reinhard R Beichel Journal: Med Phys Date: 2022-01-19 Impact factor: 4.506
Authors: Ruben Carmona; Jakub Pritz; Mark Bydder; Sachin Gulaya; He Zhu; Casey W Williamson; Christian S Welch; Florin Vaida; Graeme Bydder; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Jeffrey C Wyss; Ruben Carmona; Roshan A Karunamuni; Jakub Pritz; Carl K Hoh; Loren K Mell Journal: Radiother Oncol Date: 2015-12-07 Impact factor: 6.280
Authors: Sarah M McGuire; Sudershan K Bhatia; Wenqing Sun; Geraldine M Jacobson; Yusuf Menda; Laura L Ponto; Brian J Smith; Brandie A Gross; John E Bayouth; John J Sunderland; Michael M Graham; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2016-04-19 Impact factor: 7.038
Authors: Samantha Warren; Christopher N Hurt; Thomas Crosby; Mike Partridge; Maria A Hawkins Journal: Int J Radiat Oncol Biol Phys Date: 2017-07-29 Impact factor: 7.038
Authors: Sarah M McGuire; Yusuf Menda; Laura L Boles Ponto; Brandie Gross; Mindi TenNapel; Brian J Smith; John E Bayouth Journal: J Appl Clin Med Phys Date: 2014-07-08 Impact factor: 2.102